Tirzepatide, with a dual activity target GIP and GLP1 receptor, may have consequences for preventing or mitigating atherosclerosis due to its impact on GIPR activity
Impressive Quality The quality of this product is top notch and it was packaged very securely
For both academic and clinical cardiology, this is a call to rethink prevention: integrating metabolism, obesity, and cardiovascular risk into a single, more effective approach
aRWD: real-world data from cohort or registry studies (electronic health records, insurance-claims databases), bSRS: adverse drug reaction evidence from case reports and spontaneous-reporting systems, such as the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) and World Health Organization (WHO) VigiBase
37 , 225241.e8 (2015)
Its HIPAA-compliant patient-level data capabilities allow for precise audience targeting based on clinical, behavioral, and prescription insights